Mark Keegan, MD, FRCP(C)

 

 Buy Article Permissions and Reprints

The Guest Editor of this issue of Seminars in Neurology is Mark Keegan, MD, FRCP(C). Dr. Keegan earned his Bachelor of Arts and MD from the University of Saskatchewan. He trained in neurology at the University of Saskatchewan and was Chief Resident from 1998 to 1999. He then completed a two-year Fellowship in Neuroimmunology and Multiple Sclerosis at the Mayo Clinic in Rochester, Minnesota. He is board certified by the American Board of Psychiatry and Neurology, the Medical Council of Canada, and the Royal College of Physicians and Surgeons. He joined the faculty of the Mayo Clinic in 2001 where he is a consultant, Associate Professor of Neurology, and Chair of the Section of Multiple Sclerosis and Autoimmune Neurology.

Dr. Keegan performs clinically-based and translational research in multiple sclerosis and myelopathies. He defined a unique inflammatory CNS disease syndrome that he named Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids, or “CLIPPERS.” He is the principal investigator for Mayo Clinic on a number of multi-center clinical trials in multiple sclerosis. Dr. Keegan has received multiple honors and awards for education, and has mentored a number of young investigators. He has published extensively in prestigious peer-reviewed journals and classic neurology textbooks.

We are so very grateful to Dr. Keegan and to all of the contributors to this issue of Seminars in Neurology for sharing their expertise with us. We look forward to this new era of multiple sclerosis disease-modifying therapies and will use their manuscripts frequently to guide and inform our decisions on the best therapeutic agent for each individual patient with multiple sclerosis.